乳腺癌患者不同病理特征中H3K9ac、PD-L1、VISTA表达及其联合检测对乳腺癌不良预后的预测价值  

Expression of H3K9ac,PD-L1 and VISTA in Different Pathological Features of Breast Cancer Patients and the Value of Their Combined Detection in Predicting Poor Prognosis of Breast Cancer

作　　者：赵杰 陶璐 刘姗姗 ZHAO Jie;TAO Lu;LIU Shanshan(Department of Pathology,the First People’s Hospital of Pingdingshan City,Pingdingshan 467000,China)

机构地区：[1]平顶山市第一人民医院病理科,河南平顶山467000

出　　处：《河南医学研究》2024年第18期3357-3361,共5页Henan Medical Research

摘　　要：目的探讨乳腺癌患者不同病理特征中组蛋白H3第9位赖氨酸残基乙酰化(H3K9ac)、程序性死亡因子配体1(PD-L1)、T细胞激活抑制物免疫球蛋白的可变区结构域(VISTA)及其联合检测对乳腺癌不良预后的预测价值。方法选取2018年5月至2020年7月平顶山市第一人民医院收治的130例乳腺癌患者,免疫组化检测乳腺癌组织及癌旁组织中H3K9ac、PD-L1及VISTA表达情况。比较乳腺癌组织、癌旁组织中H3K9ac、PD-L1及VISTA表达情况;比较乳腺癌不同病理特征中H3K9ac、PD-L1及VISTA表达情况;随访3 a,根据是否发生转移、复发、死亡分为预后不良和预后良好;比较预后不良和预后良好乳腺癌患者H3K9ac、PD-L1及VISTA表达情况;分析H3K9ac、PD-L1、VISTA表达联合检测对乳腺癌不良预后的预测价值。结果乳腺癌组织中H3K9ac、PD-L1、VISTA高表达率均高于癌旁组织(P<0.05);不同组织分化程度、T分期、N分期、阳性淋巴细胞数目中H3K9ac、PD-L1、VISTA高表达率比较,差异有统计学意义(P<0.05);随访3 a,130例乳腺癌患者失访7例(5.38%),预后不良22例,预后良好101例。预后不良患者H3K9ac、PD-L1、VISTA高表达率高于预后良好患者(P<0.05);H3K9ac、PD-L1、VISTA联合检测预测乳腺癌患者不良预后的AUC为0.902,大于各指标单独预测的0.714、0.866、0.781(P<0.05)。结论乳腺癌患者癌组织中H3K9ac、PD-L1及VISTA均呈高表达,其高表达与分化程度、分期、淋巴细胞数目等病理特征相关,H3K9ac、PD-L1、VISTA联合检测对乳腺癌患者不良预后具有较高的预测价值。Objective To investigate the expression of histone H3 lysine residue 9 acetylation(H3K9ac),programmed death ligand 1(PD-L1)and V-domain immunoglobulin suppressor of T-cell activation(VISTA)in different pathological features of breast cancer patients and the value of their combined detection in predicting poor prognosis of breast cancer.Methods A total of 130 cases of breast cancer patients admitted to the First People’s Hospital of Pingdingshan from May 2018 to July 2020 were selected.The expressions of H3K9ac,PD-L1 and VISTA in breast cancer tissues and adjacent tissues were detected by immunohistochemistry.The expressions of H3K9ac,PD-L1 and VISTA in breast cancer tissues and adjacent tissues were compared.The expressions of H3K9ac,PD-L1 and VISTA in different pathological features of breast cancer were compared.After 3 years of follow-up,the patients were divided into poor prognosis and good prognosis according to metastasis,recurrence and death.The expressions of H3K9ac,PD-L1 and VISTA in breast cancer patients with poor prognosis and good prognosis were compared.The predictive value of combined detection of H3K9ac,PD-L1 and VISTA expression for poor prognosis of breast cancer was analyzed.Results The high expression rates of H3K9ac,H3K4me3,H3K27ac,PD-L1,and VISTA in cancer tissues were higher than those in para-cancerous tissues(P<0.05).The high expression rates of H3K9ac,PD-L1,and VISTA were different among different tissue differentiation levels,T stages,N stages,and the number of positive lymphocytes(P<0.05).After 3 years of follow-up,among 130 patients with breast cancer,7 cases(5.38%)were lost to follow-up,22 cases had poor prognosis and 101 cases had good prognosis.The high expression rates of H3K9ac,PD-L1,and VISTA in patients with poor prognosis were higher than those in patients with good prognosis(P<0.05).The AUC of H3K9ac,PD-L1 and VISTA combined detection for predicting poor prognosis of breast cancer patients was 0.902,which was higher than the above indicators were detected separately 0.714,0

关 键 词：乳腺癌 组蛋白H3第9位赖氨酸残基乙酰化 程序性死亡因子配体1 T细胞激活抑制物免疫球蛋白的可变区结构域 预后 

分 类 号：R737.9[医药卫生—肿瘤]